Abstract-Endothelial NO synthase (eNOS) produces superoxide when depleted of (6R) 6, 7, ) and L-arginine by uncoupling the electron flow from NO production. High expression of eNOS has been reported to have beneficial effects in atherosclerotic arteries after relatively short periods of time. However, sustained high expression of eNOS may have disadvantageous vascular effects because of uncoupling. We investigated NO and reactive oxygen species (ROS) production in a microvascular endothelial cell line (bEnd.3) with sustained high eNOS expression and absent inducible NOS and neuronal NOS expression using 4,5-diaminofluorescein diacetate and diacetyldichlorofluorescein as probes, respectively. Unstimulated cells produced both NO and ROS. After stimulation with vascular endothelial growth factor (VEGF), NO and ROS production increased. VEGF-induced ROS production was even further increased by the addition of extra L-arginine. N -nitro-L-arginine methyl ester decreased ROS production. These findings strongly suggest that eNOS is a source of ROS in these cells. Although BH 4 levels were increased as compared with another endothelial cell line, eNOS levels were Ͼ2 orders of magnitude higher. The addition of BH 4 resulted in increased NO production and decreased generation of ROS, indicating that bEnd.3 cells produce ROS through eNOS uncoupling because of relative BH 4 deficiency. Nevertheless, eNOS-dependent ROS production was not completely abolished by the addition of BH 4 , suggesting intrinsic superoxide production by eNOS. This study indicates that potentially beneficial sustained increases in eNOS expression and activity could lead to eNOS uncoupling and superoxide production as a consequence. Therefore, sustained increases of eNOS or VEGF activity should be accompanied by concomitant supplementation of BH 4 . (Hypertension. 2006;47:87-94.)
I
n the vasculature, NO is generated by endothelial NO synthase (eNOS), where it regulates vascular tone (reviewed in Reference 1 ) and affects endothelial transcription. 2 Reactive oxygen species (ROS) play a role in signal transduction and are involved in the regulation of the biologically effective concentration of NO. 3 In vascular disease states, excessive production of ROS may overwhelm the antioxidant defense mechanisms of cells, resulting in oxidative stress. 4 Interestingly, eNOS itself can produce superoxide, a process referred to as "eNOS uncoupling." 5 Reduced levels of BH 4 or L-arginine lead to uncoupling of reduced nicotinamideadenine dinucleotide phosphate (NADPH) oxidation and NO synthesis, with oxygen as terminal electron acceptor instead of L-arginine, resulting in the generation of superoxide (O 2 ⅐Ϫ ) by eNOS. 1, 6, 7 The antiatherogenic actions of NO on the vessel wall suggest that increasing eNOS expression may inhibit the development of atherosclerosis. Indeed, short-term studies on upregulation of eNOS by gene transfer of recombinant eNOS demonstrated beneficial effects in atherosclerotic arteries. 8 -10 However, longer-term high expression of eNOS may not be as beneficial. In prehypertensive spontaneously hypertensive rats (SHR), increased eNOS expression has been observed, 11 but this was associated with decreased NO release and increased superoxide production in aortic tissue, suggesting the presence of eNOS uncoupling, which may contribute to the development of hypertension and its vascular complications in the SHR. 12 Moreover, studies in apolipoprotein (apoE)-deficient mice showed that chronic overexpression of eNOS accelerated atherosclerosis, which was associated with lower NO production relative to eNOS expression and enhanced superoxide production in the endothelium. 13 Supplementation of BH 4 in these mice reduced atherosclerotic lesion size, suggesting that in these hypercholesterolemic mice, reduced BH 4 availability is involved in eNOS dysfunction during chronic eNOS overexpression.
We hypothesized that under conditions of sustained high expression of eNOS, acute stimulation of eNOS induces uncoupling of the eNOS enzyme because of a relative shortage of substrate and/or cofactors with superoxide production as a consequence. bEnd.3 cells 14 
Materials and Methods

Materials
All of the drugs were purchased from Sigma, except recombinant human VEGF 165 (Peprotech), diethylenetriamine NONOate (DETA/ NO; Cayman Chemical), H 2 O 2 (Merck), and BH 4 (Schircks Laboratories).
Cell Culture
An immortalized bEnd.3 cell line 14 was generously provided by Dr Alan Schwartz (University of Washington, St Louis, MO). Cells were cultured at 37°C in humidified 95% air-5% CO 2 in DMEM supplemented with 10% FCS, 2 mmol/L glutamine, 100 IU/mL penicillin, and 100 IU/mL streptomycin (Life Technologies).
HUVECs were harvested from freshly obtained umbilical cords by use of the method described by Jaffe et al. 15 The cells were cultured in fibronectin-coated T-flasks with EBM-2 (Bio-Whittaker) supplemented with 0.4% human fibroblast growth factor B, 0.1% human endothelial growth factor, 0.1% ascorbic acid, 0.1% gentamicin sulfate-amphotericin-B, 0.1% VEGF, 0.1% recombinant long R insulin-like growth factor, 0.1% heparin, 0.04% hydrocortisone (all supplements from Bio-Whittaker), 2% FCS (Life Technologies), 100 IU/mL penicillin, and 100 IU/mL streptomycin.
A human microvascular endothelial cell line (CDC.HMEC-1) 16 was generously provided by Dr Edwin Ades, Francisco J. Candal (Centers for Disease Control and Prevention/National Center for infectious Diseases, Atlanta, GA), and Dr Thomas Lawley (Emory University, Atlanta, GA). CDC.HMEC-1 were cultured at 37°C in humidified 95% air-5% CO 2 in MCDB 131 (Life Technologies) supplemented with 10% FCS, 10 ng/mL human endothelial growth factor, 0.05 mol/L hydrocortisone, 10 mmol/L glutamine, 100 IU/mL penicillin, and 100 IU/mL streptomycin.
Measurement of NO: 4,5-Diaminofluorescein Diacetate Assay
To measure intracellular NO production, the cell-permeable fluorescent NO indicator 4,5-diaminofluorescein diacetate (DAF-2DA; Calbiochem) was used. bEnd.3 cells were grown to confluence in a black clear-bottom 96-well plate and serum deprived for 16 hours in DMEM containing penicillin/streptomycin and 0.1% BSA. Cells were washed and incubated with 5 mol/L DAF-2DA for 40 minutes at room temperature in the dark. After incubation, cells were washed twice and incubated for 20 minutes at 37°C in the presence or absence of inhibitors or scavengers. VEGF was added, after which fluorescence was measured every 2 minutes for 70 minutes (excitation wavelength, 485 nm; emission wavelength, 538 nm; Fluoroskan Ascent, Labsystems).
To determine the reactivity of DAF-2DA toward NO, DAF-loaded bEnd.3 cells were exposed to the exogenous NO donor DETA/NO (1 to 10 mol/L), and fluorescence was measured. At the highest concentrations of DETA/NO, the cells were still viable as determined by Trypan blue staining (data not shown). The fluorescent signal increased linearly over time ( Figure 1A) . DETA/NO concentration dependently increased the DAF signal as compared with basal NO production in bEnd.3 cells (Figure 1b) , demonstrating time-and concentration-dependent linearity for the DAF assay of NO production.
Treating bEnd.3 cells with H 2 O 2 (1 to 10 mol/L) increased fluorescence ( Figure 1C) ; however, N -nitro-L-arginine methyl ester (L-NAME) attenuated the increase in DAF signal, implying H 2 O 2 -induced eNOS activation rather than direct oxidation of DAF-2 by H 2 O 2 .
Measurement of ROS: Diacetyldichlorofluorescein Diacetate Assay
Intracellular ROS were measured using diacetyldichlorofluorescein diacetate (CM-H 2 DCFDA; Molecular Probes), a nonfluorescent cell-permeable indicator for ROS. Cells were seeded in a clear 96-well plate and treated as in the DAF-2DA assay. 
Measurement of Biopterin Levels in Cell Lysates
Biopterin levels in lysates of bEnd.3 cells or CDC.HMEC-1 were determined as described previously. 17 Briefly, cell pellets from T-flasks were lysed in cold extract buffer [50 mmol/L Tris-HCl, 1 mmol/L DTT, 1 mmol/L EDTA, and 0.4 mol/L 6,7-dimethylpterine (pH7.4)]. Protein concentration was measured using the Pierce BCA protein assay. The whole procedure was performed in the dark. Proteins were removed by adding 10 L of a 1:1 mixture of 1.5 mol/L HClO 4 and 2 mol/L H 3 PO 4 to 90 L of extracts followed by centrifugation. Total biopterins [BH 4 , 7,8-dihydro-L-biopterin (BH 2 ), and biopterin] were determined by acid oxidation. Therefore, 10 L of 1% iodine in 2% KI solution was added to 90 L protein-free supernatant. BH 2 and biopterin were determined by alkali oxidation by adding 10 L of 1 mol/L NaOH to 80 L of extract followed by 10 L of iodine/KI solution. Samples were incubated at room temperature for 1 hour. Alkaline-oxidation samples were acidified with 20 L of 1 mol/L H 3 PO 4 . Iodine was reduced by adding 5 L of fresh ascorbic acid (20 mg/mL).
Pterines were measured by high-performance liquid chromatography (HPLC) on a Waters 600E HPLC (Etten-Leur 
Protein Measurements
To confirm high expression of eNOS and rule out expression of inducible NO synthase (iNOS) or neuronal NOS, bEnd.3 cells, HUVECs, and CDC.HMEC-1 were lysed [20 mmol/L Tris-HCl, 150 mmol/L NaCl, 1 mmol/L EDTA, 1 mmol/L EGTA, 1% Triton-X100, and protease inhibitors (MiniComplete, Roche Diagnostics Corporation; pH 7.4)]. Cell extracts and positive control protein supplied with antibodies were subjected to SDS-PAGE and transferred to polyvinylidene fluoride membrane. Blots were incubated with monoclonal antibodies against eNOS, nNOS (Transduction Laboratories), and iNOS (Alexis) and subsequently with a horseradish peroxidase-conjugated rabbit anti-mouse antibody (Jackson Immunochemicals). Membrane-bound antibodies were visualized using chemiluminescence reagent (Roche).
Expression of eNOS was also determined using an ELISA. A polyclonal rabbit antibody raised against a recombinant fragment spanning residues 1 to 67 of bovine eNOS (unpublished data) was bound to microtiter plates (NUNC-Immuno Plate Maxisorb Surface, NUNC) by incubation at 4°C. Plates were washed 3 times in Tris buffer [50 mmol/L Tris-HCl and 150 mmol/L NaCl (pH7.4)] with 0.1% Tween 20 and then incubated with 3% BSA in Tris buffer with 0.05% Tween 20 for 2 hours at room temperature. Samples were incubated in a total volume of 50 L for 2 hours at room temperature. Plates were thoroughly washed 3 times and incubated for 2 hours at room temperature with 100 L of 125 ng/mL eNOS antibody (Transduction Laboratories) in Tris buffer with 0.1% BSA and 0.05% Tween 20. Subsequently, plates were incubated with 650 g/mL horseradish peroxidase-conjugated rabbit anti-mouse antibody (Jackson Immunochemicals) in Tris buffer with 0.1% BSA and 0.05% Tween 20 for 2 hours at room temperature. A color reaction was observed by incorporating 3,3Ј,5,5Ј-tetramethyl-benzidine into the reaction, which was stopped by adding 50 L of 2 mol/L H 2 SO 4 . The optical density was measured at 450 nm in a microplate reader (Multiskan Ascent, Labsystems). The assay was validated using a dilution series of bEnd.3 cells. The interassay variability was 5Ϯ2%, whereas the intraassay variability was 2.0Ϯ0.8%.
Calculations and Statistical Analysis
NO and ROS production was calculated by determining the slopes of each line with linear regression. Results were expressed relative to control. Statistical comparisons were made by 1-way or 2-way ANOVA, as required. Subsequent post hoc testing was done with the Student-Newman-Keuls test. P values Ͻ0.05 were considered statistically significant.
Results eNOS in bEnd.3 Cells Is, in Part, in an Uncoupled State
To identify the source of NO production in bEnd.3 cells, expression levels of eNOS, nNOS, and iNOS were determined. High expression of eNOS and the absence of iNOS or nNOS protein were confirmed by Western blot (Figure 2A ). Incubation of bEnd.3 cells with the DCF probe resulted in a fluorescent signal, which was decreased 18% (PϽ0.05) by the addition of L-NAME. Because CM-H 2 DCFDA is not reactive toward NO (Figure 1E ), these data show that, other than NO production, there is constitutive eNOS-dependent formation of ROS, that is, uncoupling, in the basal state.
VEGF Enhances eNOS-Dependent NO Production but Also ROS Production in bEnd.3 Cells
VEGF induced a concentration-dependent increase in eNOSdependent NO production ( Figure 2B ). VEGF also significantly increased eNOS-dependent ROS production ( Figure  3) . In VEGF-stimulated cells, the addition of L-NAME resulted in a 35% (PϽ0.05) decrease in the DCF signal versus an 18% (PϽ0.05) decrease in DCF signal in nonstimulated cells.
eNOS Uncoupling Is Because of Relative Shortage of BH 4 but Not Because of Shortage of L-Arginine
Shortage of BH 4 can lead to eNOS uncoupling. Determination of biopterin levels in bEnd.3 cells and CDC.HMEC-1 revealed that BH 4 levels are Ϸ8 times increased in bEnd. Effect of VEGF and L-arginine on eNOS-dependent ROS production. bEnd.3 cells were loaded with CM-H 2 DCFDA and stimulated with VEGF in the presence and absence of L-NAME. Results plotted as eNOS-dependent ROS production (difference between total ROS production and eNOSindependent ROS production).
tion at 3 and 10 mol/L ( Figure 5A ). A similar result was obtained with VEGF. ROS levels showed a tendency to decrease in the presence of BH 4 (1 to 10 mol/L; Figure 5B ). A similar result was found in the presence of VEGF. To exclude any antioxidant effects of BH 4 , NH 4 was used as a negative control. The addition of 10 mol/L NH 4 had no effects on NO production and decreased ROS production in bEnd.3 cells (Figure 6 ).
Because eNOS uncoupling can also be caused by a shortage of the substrate L-arginine, the effect of additional L-arginine on NO and ROS production was determined. In the presence of high L-arginine levels (500 mol/L), the addition of BH 4 did not significantly increase basal NO production and also had no effect on VEGF-induced NO production ( Figure  5A ). Increasing L-arginine concentrations up to 500 mol/L did not affect the basal ROS production but did lead to a significant increase in eNOS-dependent ROS production in the presence of VEGF (Figure 3 ). In the presence of high L-arginine levels, ROS production was significantly decreased after the addition of 3 and 10 mol/L BH 4 , both in the absence and presence of VEGF ( Figure 5B ).
Other Potential ROS Sources
Diphenyleneiodonium (DPI) was used to identify flavincontaining enzymes as possible ROS sources. Incubation of bEnd.3 cells with DPI lead to a significant 20% (PϽ0.05) decrease in basal ROS production ( Figure 7 ) and a 25% (PϽ0.05) decrease in the presence of VEGF (data not shown). To determine whether NADPH oxidase, xanthine oxidase, and mitochondria are possible ROS sources, bEnd.3 cells were incubated with apocynin, oxypurinol, and thenoyltrifluoroacetone (TTFA), respective inhibitors of these oxidase systems. Apocynin and TTFA had no effect on the DCF signal ( Figure 7) . Oxypurinol decreased ROS production slightly in the absence (Figure 7) but not in the presence of VEGF (data not shown). DPI and oxypurinol were also combined with L-NAME, resulting in an additional decrease in ROS production as compared with the effect of the separate inhibitors ( Figure 7) .
To exclude the involvement of peroxynitrite (ONOO 
Discussion
It has been proposed that long-term elevation of eNOS expression may require adjustments in tetrahydrobiopterin metabolism, 6 which could explain the controversial results between studies on prolonged 12,13 and short-term eNOS overexpression. 8 -10 The present study demonstrates that bEnd.3 cells chronically express high eNOS levels but do not express the other NOS isoforms. With respect to eNOS, bEnd.3 cells are relatively deficient in BH 4 as compared with other endothelial cells. As a consequence, eNOS is partially in the uncoupled state. Stimulation of eNOS activity in these cells by VEGF enhanced ROS production, particularly at high L-arginine concentrations, which was corrected to a substantial degree by BH 4 . Our data suggest that under conditions of chronically increased eNOS expression and particularly if eNOS activity is stimulated, a relative shortage of BH 4 may lead to eNOS uncoupling, resulting in superoxide production. Our results are in line with observations by Ozaki et al, 13 who demonstrated that overexpression of eNOS in the endothelium promoted atherosclerosis in apoE-knockout mice. Dysfunctional eNOS and subsequent increased superoxide production seems to be responsible for the progression of atherosclerosis in these animals, mainly caused by a deficiency of the cofactor BH 4 . In agreement with this study, Cosentino et al 12 showed that increased eNOS expression in SHR is also associated with dysfunctional eNOS, which may contribute to the development of hypertension and its vascular complications in these rats.
bEnd.3 cells are particularly useful for studying eNOS uncoupling, because NADPH oxidase, which is a major source of ROS in endothelial cells, 18 does not contribute to ROS production in these cells. The combined results of this study show that the ROS production in bEnd.3 cells is eNOS dependent, implying that eNOS in bEnd.3 cells is partly in an uncoupled state.
We hypothesized that activation of the enzyme would enhance ROS production. Indeed, stimulation with VEGF increased eNOS-dependent ROS production. This is in line with studies in other endothelial cells that show an eNOS-dependent increase in ROS production after VEGF stimulation. 19, 20 We and others found a decrease in eNOS-dependent ROS production after addition of L-NAME, whereas Colavitti et al 19 reported the opposite. The latter observation is consistent with the common perspective that inhibition of functional NOS and, thus, blockage of NO production, results in the loss of the NO-scavenging effect and, thus, increased O 2 ⅐Ϫ levels. On the other hand, inhibition of dysfunctional NOS will lead to a decrease in ROS production because of the coupling state of eNOS. [21] [22] [23] [24] eNOS dysfunction and subsequent O 2 ⅐Ϫ production is commonly thought to result from a shortage of BH 4 . 6 In the present study, the addition of BH 4 resulted in a significant increase in NO production in bEnd.3 cells, whereas ROS levels showed a tendency to decrease. NH 4 was used as a negative control, because it exerts antioxidant effects but has no influence on eNOS uncoupling. The addition of NH 4 had no effect on NO production and decreased ROS production in bEnd.3 cells. From these results, it can be concluded that the decreased ROS production in the presence of BH 4 is because of a decrease in eNOS uncoupling and not caused by antioxidant effects of BH 4 . In line with these results, it has been shown that overexpression of GTP-cyclohydrolase I, the rate-limiting enzyme in BH 4 synthesis, reduced endothelial dysfunction in apoE-knockout mice. 25 In addition, GTPcyclohydrolase I-knockout mice, which are deficient in BH 4 , showed hypertension and increased vascular superoxide production. The latter was inhibited by N G -methyl-L-arginine acetate, indicating that ROS was generated by uncoupled eNOS. 21 Other than BH 4 deficiency, shortage of the substrate L-arginine could theoretically lead to uncoupling of eNOS. 1 However, there is limited evidence on the role of L-arginine in eNOS dysfunction. 26, 27 Moreover, there is no consensus on whether supplementation of L-arginine is beneficial under conditions of endothelial dysfunction. Some studies in animals and humans show restored endothelial function, 28, 29 whereas others fail to show a beneficial effect of L-arginine. 30 -32 Chen et al 33 found that chronic treatment with L-arginine negated the positive effect of iNOS deficiency in apoE/iNOS double-knockout mice. Furthermore, diabetic rats showed increased ROS production after the addition of L-arginine, which was partly reduced by the addition of L-NAME and DPI and the addition of BH 4 . 24 Our results indicate that a shortage of L-arginine is not causing eNOSdependent ROS production in bEnd.3 cells. In fact, increasing the L-arginine concentration enhanced VEGF-induced ROS production. There are 2 possible explanations for these findings. First, increased L-arginine levels have been associated with an increase in total biopterin levels, but unaltered BH 4 levels, suggesting that L-arginine supplementation leads to oxidation of biopterin. 33 Second, increased O 2 ⅐Ϫ production in the presence of L;arginine might be because of increased calmodulin binding and a resulting increased electron flow through the enzyme, 34, 35 leading to a relatively augmented shortage of BH 4 . The mechanism through which increasing levels of L-arginine enhances ROS production by increasing L-arginine levels in bEnd.3 cells is unclear.
Although the addition of BH 4 led to a reduction of ROS production in bEnd.3 cells, it did not completely abolish ROS production. These results correspond with the in vitro study with the purified enzyme, 7 in which BH 4 only partly inhibited uncoupling of the purified eNOS enzyme. We identified xanthine oxidase as an additional source of ROS in bEnd.3 cells under basal conditions. ONOO Ϫ , NADPH oxidase, and mitochondria were excluded as contributors to ROS production in bEnd.3 cells.
Several reports have been published on intrinsic superoxide production by NO synthases. For nNOS, it has been reported that ROS are produced by the haem group. 36 For iNOS and eNOS, however, the source of ROS production is unclear. Some reports suggest that both the haem and the flavin domain in eNOS produce superoxide. 27, 37 In bEnd.3 cells, the addition of DPI led to a decrease in but not complete inhibition of ROS production, indicating that flavins are not involved in the intrinsic ROS production by eNOS in these cells. These data suggest that the source of the remaining eNOS-dependent ROS production in bEnd.3 cells, even in the presence of additional BH 4 , is probably the haem group in eNOS. 27, 7, 37 
Perspectives
Although eNOS gene transfer has been proposed to be useful in the treatment of endothelial dysfunction, 8 -10 we now show that sustained high expression of eNOS protein results in ROS production because of uncoupling. eNOS-dependent ROS production in bEnd.3 cells is partly corrected by BH 4 supplementation. These findings suggest that attempts to improve endothelial function, by sustained increases of eNOS expression and activity, for instance by gene transfer of eNOS or VEGF, should be accompanied by concomitant increases of BH 4 to prevent eNOS uncoupling.
